Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The cell biology behind the oncogenic PIP3 lipids

  • Carrera, Ana C.
  • Anderson, Richard
The different mechanisms of phosphoinositide 3-kinase (PI3K) activation in cancer as well as the events that result in PI3K pathway reactivation after patient treatment with PI3K inhibitors was discussed on October 15–17th, 2018, in the medieval town of Baeza (Universidad Internacional de Andalucía, Spain) at the workshop entitled ‘The cell biology behind the oncogenic PIP3 lipids’. These topics and the data presented regarding cellular functions altered by PI3K deregulation, the cooperation of PI3K/PTEN mutations with other tumor drivers, and the lessons learned for PI3K-targeted therapy, are discussed below., Work in the group of ACC is financed by grants from the Ministerio de Ciencia e Innovación (Spanish Ministry of Science and Innovation; SAF2016-79195), the Madrid regional government (BMD-3804), the Fundación Ramón Areces and the Fundación Científica Asociación Española Contra el Cáncer (16035CARR).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Opposing Roles of PIK3R1/p85α and PIK3R2/p85β in Cancer

  • Vallejo-Díaz, Jesús
  • Chagoyen, Mónica
  • Olazabal-Morán, Manuel
  • González García, Ana
  • Carrera, Ana C.
Dysregulation of the PI3K/PTEN pathway is a frequent event in cancer, and PIK3CA and PTEN are the most commonly mutated genes after TP53. PIK3R1 is the predominant regulatory isoform of PI3K. PIK3R2 is an ubiquitous isoform that has been so far overlooked, but data from The Cancer Genome Atlas shows that increased expression of PIK3R2 is also frequent in cancer. In contrast to PIK3R1, which is a tumor-suppressor gene, PIK3R2 is an oncogene. We review here the opposing roles of PIK3R1 and PIK3R2 in cancer, the regulatory mechanisms that control PIK3R2 expression, and emerging therapeutic approaches targeting PIK3R2., We thank Kenneth McCreath for editorial assistance, and the Spanish Ministry of Science and Innovation (SAF2016-79195), the Madrid regional government (BMD-3804), the Ramón Areces Fund, and the Fundación Científica Asociación Española Contra el Cáncer (16035CARR) for funding support
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PI3Kβ-regulated β-catenin mediates EZH2 removal from promoters controlling primed human ESC stemness and primitive streak gene expression

  • Yadav, Sudhanshu
  • Garrido, Antonio
  • Hernández, M. Carmen
  • Oliveros, Juan C.
  • Pérez-García, Vicente
  • Fraga, Mario F.
  • Carrera, Ana C.
The mechanism governing the transition of human embryonic stem cells (hESCs) toward differentiated cells is only partially understood. To explore this transition, the activity and expression of the ubiquitous phosphatidylinositol 3-kinase (PI3Kα and PI3Kβ) were modulated in primed hESCs. The study reports a pathway that dismantles the restraint imposed by the EZH2 polycomb repressor on an essential stemness gene, NODAL, and on transcription factors required to trigger primitive streak formation. The primitive streak is the site where gastrulation begins to give rise to the three embryonic cell layers from which all human tissues derive. The pathway involves a PI3Kβ non-catalytic action that controls nuclear/active RAC1 levels, activation of JNK (Jun N-terminal kinase) and nuclear β-catenin accumulation. β-Catenin deposition at promoters triggers release of the EZH2 repressor, permitting stemness maintenance (through control of NODAL) and correct differentiation by allowing primitive streak master gene expression. PI3Kβ epigenetic control of EZH2/β-catenin might be modulated to direct stem cell differentiation., This work was funded by the Spanish Ministry of Science, Innovation and Universities (SAF2016-79195-R and PID2019-106937RB-I00), by the Madrid Regional Government (S2017/BMD-3804), and by the Spanish Association Against Cancer (16035CARR). V.P.-G. was supported by the Spanish Ministry of Science and Innovation (RYC-2019-026956 and PID2020-114459RA-I00).